Yet fewer than 1 in 10 patients ever file an appealthose who do have a real chance of getting coverage
Eleftheriadou A, Riley D, Zhao SS et al (2024) Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database
This is what causes nausea, headaches, and the metallic taste many patients report 48 hours post-injection
The GH/IGF-1 axis declines with age, and secretagogues can transiently raise it, but restoring a biomarker toward youthful levels has never been shown to equal restored youthful function and some GH-axis interventions carry theoretical risks that make the anti-aging framing particularly premature
For a deeper class comparison, see our mazdutide vs tirzepatide vs retatrutide breakdown
Gydesen S, Hjuler ST, Freving Z, Andreassen KV, Sonne N, Hellgren LI, et al